Pharmacological interactions of statines with non-insulinal antidiabetic agents
DOI:
https://doi.org/10.47196/diab.v51i2.68Keywords:
statins, pharmacological interactions, non-insulinal antidiabetic agentsAbstract
Introducción: dislipemia prevalence in type 2 diabetes is very often, between 35 to 56%; and despite new therapeutic options, statins continue being the drugs of first choice for treatment.
Objectives: analyze the possible pharmacological interactions between statins and non-insulin drugs used in type 2 diabetic patients to normalize blood glucose. Inhibition of statins on HMG-CoA is highly selective, so pharmacodynamic interactions are not expected. But regarding pharmacokinetics, there are several levels where interactions with other drugs may occur. Three main levels of pharmacokinetic interactions have been described so far: membrane transporter OATP1B1, cytochrome P450 and absorption.
Materials and methods: bibliographic review
Conclusions: after analyzing the interaction of statins with metformin, sulfonylureas, thiazolidinediones, DPP4 inhibitors, GLP-1 agonists and SGLT2 inhibitors, we conclude that
the availability of studies of pharmacological interactions in type 2 diabetic patients is scarce. Some interactions that modify AUC and Cmax were described, but no clinical implications were evident.
References
Szalat A, et al. Managing dyslipidemia in type 2 diabetes mellitus. Best Practice & Research Clinical Endocrinology & Metabolism 2016; 30:431-444.
Taskinen M, et al. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis 2015; 239:483-495.
Srikanth S. Management of dyslipidemia in patients with hypertension, diabetes and metabolic syndrome. Curr Hypertens Rep 2016; 18:76.
Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundamental & Clinical Pharmacology 2004; 19:117-125.
Liao JK. Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol 2002; 86:5-18.
Lennerniis H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors similarities and differences. Clin Pharmacokinet 1997; 32 (5): 403-425.
Corsini A, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacology & Therapeutics 1999; 84:413-428.
FDA Drug Safety Communication: Baycol (cerivastatin sodium tablets) Aug 2001. Disponible en: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm172268.htm
Bellosta S, Corsini A. Statin drug interactions and related adverse reactions. Expert Opinion on Drug Safety 2012; 11:933-946.
McKenney J. Pharmacologic characteristics of statins. Clin Cardiol 2003; 26 (Suppl III):32-38.
García MJ, et al. Clinical pharmacokinetics of statins. Methods find. Exp Clin Pharmacol 2003; 25(6): 457-481.
Pertti J, et al. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clinical Pharmacology and Therapeutics 2006; 80(6):565-581.
Sorokin A. Rhabdomyolysis associated with pomegranate juice consumption. Am J Cardiol 2006; 98(5):705-6.
Hirota T, Ieiri I. Drug-drug interactions that interfere with statin metabolism. Expert Opinion on Drug Metabolism & Toxicology 2015; 11:1435-1447.
Schelleman H, Han X, Brensinger CM, et al. Pharmacoepidemiologic and “in vitro” evaluation of potential drug-drug interactions of sulfonylureas with fibrates and statins. Br J Clin Pharmacol 2014; 78: 639-648.
Leonard CE, Bilker WB, Brensinger CM, et al. Severe hypoglycemia in users of sulfonylurea antidiabetic agents and antihyperlipidemics. Clinical Pharmacology & Therapeutics 2016; 99; 538-547.
Van de Steeg E, Grupink R, Schreurs M, et al. Drug-drug interactions between rosuvastatin and oral antidiabetic drugs occurring at the Level of OATP1B1. Drug Metab Dispos 2013; 41: 592-601.
Amin M, et al. Pharmacotherapy of type 2 diabetes mellitus: an update on drug-drug interactions. Drug Saf 2014; 37:903-919.
Bachmakov I, Glaeser H, Fromm MF, et al. Interaction of oral antidiabetic drugs with hepatic uptake transporters focus on organic anion transporting polypeptides and organic cation transporter. Diabetes 2008; 57: 1463-69.
Lee D, et al. Pharmacokinetic interaction between rosuvastatin and metformin in healthy Korean male volunteers: a randomized, open-label, 3-period, crossover, multiple- dose study. Clinical Therapeutics 2014; 36: 1171-1181.
Kasichayanula S, et al. Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. Adv Ther 2012; 29(2):163-77.
Macha S, Lang B, Pinnetti S, et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 inhibitor, and simvastatin following co-administration in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics 2014; 52:973-980.
Malm-Erjefält M, et al. Effect on the gastrointestinal absorption of drugs from different classes in the biopharmaceutics classification system, when treating with liraglutide. Mol Pharmaceutics 2015; 12, 4166−4173.
Kothare PA, et al. Effect of exenatide on the steady-state pharmacokinetics of digoxin. J Clin Pharmacol 2005; 45(9):1032-7.
Sheen A, et al. Dipeptidyl peptidase-4 inhibitors (gliptins) focus on drug-drug interactions. Clin Pharmacokinet 2010; 49 (9): 573-588.
Patel CG, et al. Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole. Clin Pharmacol 2011; 2: 13-25.
Bergman AJ, et al. Effect of sitagliptin on the pharmacokinetics of simvastatin. J Clin Pharmacol 2009; 49: 483-8.
Kao DP, et al. Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. Diabet Med 2008; 25: 1229-30.
DiGregorio RV, et al. Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction. Pharmacotherapy 2009; 29: 352-6
Graefe-Mody U, et al. Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin. Int J Clin Pharmacol Ther 2010; 48: 367-74.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
